The Future of Endoscopy with Doug Rex, MD

BySameer K. Berry, MD, MBA

ByWilliam D. Chey, MD, AGAF, FACG

ByDouglas K. Rex, MD, MACP, MACG, MASGE, AGAF

In this podcast episode, Douglas Rex, MD, discusses the importance of intent-to-treat for colorectal screenings, how screening technology has transformed gastroenterology practice and more.

Intro :02
Welcome to this episode of Gut Talk :23
The interview/about Rex :32
Where did you grow up, and what was your childhood like? :52
What got you interested in medicine? 2:50
How did your journey with GI start? 4:33
How have those early days and formidable experiences of being in the lab impacted your career today and what you are more well-known for? 8:19
Discussion on the NEJM study and the debates surrounding methodologies for endoscopy 11:55
Rex, Chey and Berry on the importance on the issue surrounding intent-to-treat in the setting of colorectal cancer screening 14:57
Rex on the Multi-Society Task Force of Colorectal Cancer (MSTF) committee and how they come to decisions that influence how gastroenterologists practice daily 16:55
Was it a difficult decision to move the threshold for colorectal cancer screening from 50 to 45? 20:41
In an environment where there is a limited resource such as colonoscopy, are you struggling with volume at your institution? … What are some strategies that listeners can utilize to prioritize patients, seek other possibilities and manage volume? 22:28
What’s the right way to approach the screening problem? … Where will this lead us ten years from now if all of us are spending our time in the endoscopy suite because of continued reduction in the age of screening while the prevalence of functional conditions and chronic diseases is also rising? 25:51
How long do you think we’ll continue to rely upon screening colonoscopy as one of our primary means by which to screen for colon cancer? Are there any technologies on the horizon that will eat into the share of screening colonoscopy? 28:55
What is your perspective on AI and how it can impact not only adenoma detection rate and polyp detection, but also clinical workflows such as documentation time? … Are you concerned about the new generation of clinicians being trained on and relying on these tools? 34:07
What have you learned in terms of best practices for the right and wrong ways to work with industry? 38:07
Thank you, Dr. Rex 40:25
Thanks for listening 40:43

Douglas K. Rex, MD, is a distinguished professor emeritus at Indiana University School of Medicine and a full-time clinical gastroenterologist at Indiana University Hospitals.

We’d love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on Twitter @HealioGastro @sameerkberry @umfoodoc. For more from Dr. Rex, follow @Rex_colonoscopy on Twitter.

Published by:

Sources/Disclosures

Collapse

Disclosures: Chey and Berry report no relevant financial disclosures. Rex is a consultant for Boston Scientific, Braintree Laboratories, Medtronic, Norgine, and Olympus Corporation. He provides research support at Braintree Laboratories, Erbe USA Inc, Medivators, and Olympus Corporation and is a shareholder of Satisfai Health.

Read more

The Future of Endoscopy with Doug Rex, MD

Gut Talk

Related Content